Response of the insulin-like growth factor (IGF) system to IGF-IR inhibition and androgen deprivation in a neoadjuvant prostate cancer trial: effects of obesity and androgen deprivation. [electronic resource]
Producer: 20130705Description: E820-8 p. digitalISSN:- 1945-7197
- Adenocarcinoma -- complications
- Androgen Antagonists -- administration & dosage
- Anilides -- administration & dosage
- Antibodies, Monoclonal -- administration & dosage
- Antibodies, Monoclonal, Humanized
- Antineoplastic Agents -- administration & dosage
- Antineoplastic Combined Chemotherapy Protocols -- administration & dosage
- Body Mass Index
- Cohort Studies
- Goserelin -- administration & dosage
- Humans
- Insulin -- blood
- Insulin Resistance
- Insulin-Like Growth Factor Binding Protein 1 -- blood
- Male
- Neoadjuvant Therapy
- Nitriles -- administration & dosage
- Obesity -- complications
- Prostatectomy
- Prostatic Neoplasms -- complications
- Receptor, IGF Type 1 -- antagonists & inhibitors
- Risk
- Secondary Prevention
- Somatomedins -- analysis
- Tosyl Compounds -- administration & dosage
- United States -- epidemiology
No physical items for this record
Publication Type: Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
There are no comments on this title.
Log in to your account to post a comment.